Table 2.
Other treatments prescribed in the main analysis (fidaxomicin-treated) population.
| Number of patients, N = 294 | ||
|---|---|---|
| Treatments prescribed for the CDI episode before fidaxomicin | ||
| Any treatment | Treated, n/N (%) | 98/289 (33.9) |
| Metronidazole (oral) | Treated, n/N (%) | 47/98 (48.0) |
| Dosage, Ng/day, mean (SD) | 461.5 (0.1) | |
| g/day, median (IQR) | 1.5 (1.5, 1.5) | |
| Vancomycin (oral) | Treated, n/N (%) | 57/98 (58.2) |
| Dosage, ng/day, mean (SD) | 560.7 (0.4) | |
| g/day, median (IQR) | 0.5 (0.5, 0.5) | |
| Metronidazole (IV) | Treated, n/N (%) | 9/98 (9.2) |
| Dosage, Ng/day, mean (SD) | 81.2 (0.5) | |
| g/day, median (IQR) | 1.5 (0.8, 1.5) | |
| Other treatmenta | Treated, n/N (%) | 5/98 (5.1) |
| Concomitant treatment | ||
| Any treatment | Treated, n/N (%) | 28/289 (9.7) |
| Metronidazole (oral) | Treated, n/N (%) | 4/28 (14.3) |
| Dosage, Ng/day, mean (SD) | 41.4 (0.3) | |
| g/day, median (IQR) | 1.5 (1.3, 1.5) | |
| Vancomycin (oral) | Treated, n/N (%) | 7/28 (25.0) |
| Dosage, Ng/day, mean (SD) | 71.2 (0.8) | |
| g/day, median (IQR) | 1.0 (0.5, 2.0) | |
| Metronidazole (IV) | Treated, n/N (%) | 6/28 (21.4) |
| Dosage, Ng/day, mean (SD) | 61.3 (0.4) | |
| g/day, median (IQR) | 1.5 (1.5, 1.5) | |
| Faecal microbiota transplantation | Treated, n/N (%) | 1/27 (3.7)b |
| Other | Treated, n/N (%) | 17/26 (65.4) |
aFive patients had previously received treatment with ceftriaxone (n = 1, one treatment), ofloxacin (n = 1, one treatment) and vancomycin (n = 5, seven treatments).
bA 93-year-old female patient with recurrent infection received both fidaxomicin and faecal microbiota transplantation (date of latter unknown). Clinical cure was reported at 2 days after the end of fidaxomicin treatment, and no recurrences of infection were reported for this patient.
CDI, Clostridioides difficile infection; IQR, interquartile range; IV, intravenous; n, number of patients treated; N, number of patients with information available; SD, standard deviation.